Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Santen Pharmaceutical Co ( (JP:4536) ) has issued an update.
Santen Pharmaceutical Co., Ltd. has announced the disposal of treasury shares as part of its Performance Share Unit plan, a performance-linked stock remuneration initiative aimed at providing medium- to long-term incentives for its directors and corporate officers. This move, approved at the company’s Annual General Meeting, reflects Santen’s commitment to aligning management interests with shareholder value, as evidenced by the payout ratios based on performance metrics such as total shareholder return and ESG-related criteria.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2600.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a company based in Osaka, Japan, primarily operating in the pharmaceutical industry. The company focuses on developing and providing pharmaceutical products, particularly in the field of ophthalmology, to enhance the quality of life for patients worldwide.
Average Trading Volume: 1,380,880
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen543B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.